Toronto-based Canadian Imperial Bank of Commerce (CM - Free Report) is expanding its presence in the United States. The company has inked a deal to acquire Milwaukee, WI-based Cleary Gull Inc., a boutique investment banking firm.
Acquisition of Cleary Gull, which specializes in middle market M&As, private capital placement and debt advisory across the United States, will expand Canadian Imperial’s deal-making capabilities. Notably, the terms of the deal, expected to close in the fourth quarter of 2019, remain undisclosed.
Canadian Imperial already has a U.S. capital markets presence in New York, Chicago and Houston. The company plans to integrate Cleary Gull operations with its existing Chicago-based investment banking division.
Canadian Imperial made Chicago its U.S. headquarters following the acquisition of PrivateBancorp in 2017. Since then, the bank has been pursuing to expand its “capabilities through a highly integrated approach across Commercial Banking, Wealth Management and Capital Markets.”
Michael Capatides, senior executive vice-president and group head, US Region, and president & CEO, CIBC Bank USA, said, “This acquisition is a further investment in our North American platform that will deliver enhanced Capital Markets capabilities for our clients, and support our diversification and growth objectives.”
Further, Ronald Miller, Cleary Gull’s president in the statement said, “With our focus on family and entrepreneur-owned business, as well as private equity firms, we are excited about the opportunities for our clients and our team as part of CIBC's growing business in the US.”
With Canadian Imperial facing a tough operating backdrop in Canada, this deal is expected to support its revenues, which are getting hampered by lower rates and muted loan growth. Also, the company is facing heightening competition from other Canadian banks, including The Toronto-Dominion Bank’s (TD - Free Report) , Bank of Montreal (BMO - Free Report) and Royal Bank of Canada (RY - Free Report) , among others.
Moreover, shares of this Zacks Rank #5 (Strong Sell) company have rallied 5.6% so far this year, underperforming the industry’s rise of 8.6%.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>